Clinical Trial Update: Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease [Phase 3]

View source ↗

Summary

This document reports a Phase 3 extension study to evaluate the safety and tolerability of 24-hour daily exposure to continuous subcutaneous infusion of ABBV-95…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ABBV-951

Snippet

Sponsor: AbbVie | Conditions: Parkinson's Disease (PD) | Phase 3 | Status: ACTIVE_NOT_RECRUITING